Evidence map›Paper›PMID 31709530›Full record

ArticleInternational journal of cancer2020

COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk.

Donovan Watza, Christine M Lusk, Gregory Dyson, Kristen S Purrington, Angela S Wenzlaff, Christine Neslund-Dudas, Ayman O Soubani, Shirish M Gadgeel, Ann G Schwartz

Open access · bronzeAbstract read
In one paragraph

Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis.International journal of chronic obstructive pulmonary disease · 2022
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Donovan WatzaDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI.
Christine M LuskDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI.
Gregory DysonDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI.
Kristen S PurringtonDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI.
Angela S WenzlaffDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI.
Christine Neslund-DudasDepartment of Public Health Sciences, Henry Ford Health System and Henry Ford Cancer Institute, Detroit, MI.
Ayman O SoubaniKarmanos Cancer Institute, Detroit, MI.
Shirish M GadgeelComprehensive Cancer Center, University of Michigan, Ann Arbor, MI.
Ann G SchwartzDepartment of Oncology, Wayne State University School of Medicine, Detroit, MI.
The Barbara Ann Karmanos Cancer Institute · USWayne State University · USHenry Ford Health System · USMichigan Cancer Research Consortium · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI Julie Lynn Boerner · 1985 to 2026
$68.4M
Inflammation Pathways and COPD in the Development of Lung CancerR01CA141769 · NCI · WAYNE STATE UNIVERSITY · PI SCHWARTZ, ANN G. · 2011 to 2016
$8.7M
TRAINING PROGRAM IN THE BIOLOGY OF CANCERT32CA009531 · NCI · WAYNE STATE UNIVERSITY · PI Larry H Matherly · 1985 to 2026
$5.3M
NCI NIH HHS P30 CA022453NCI NIH HHS R01 CA141769NCI NIH HHS T32 CA009531
6 · The paper itself

Abstract

Genome-wide association studies (GWAS) have identified several loci contributing to lung cancer and COPD risk independently; however, inflammation-related pathways likely harbor additional lung cancer risk-associated variants in biologically relevant immune genes that differ dependent on COPD. We selected single nucleotide polymorphisms (SNPs) proximal to 2,069 genes within 48 immune pathways. We modeled the contribution of these variants to lung cancer risk in a discovery sample of 1,932 lung cancer cases and controls stratified by COPD status and validation sample of 953 cases and controls also stratified by COPD. There were 43 validated SNPs in those with COPD and 60 SNPs in those without COPD associated with lung cancer risk. Furthermore, 29 of 43 and 28 of 60 SNPs demonstrated a statistically significant interaction with COPD in the pooled sample. These variants demonstrated tissue-dependent effects on proximal gene expression, enhanced network connectivity and resided together in specific immune pathways. These results reveal that key inflammatory related genes and pathways, not found in prior GWAS, impact lung cancer risk in a COPD-dependent manner. Genetic variation identified in our study supplements prior lung cancer GWAS and serves as a foundation to further interrogate risk relationships in smoking and COPD populations.

Indexed as

Gene Regulatory NetworksImmunityPolymorphism, Single NucleotideAdultAgedAged, 80 and overCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansLung NeoplasmsMaleMiddle AgedOrgan SpecificityPulmonary Disease, Chronic ObstructiveCOPDinflammationlung cancertargeted genetic variation

Identifiers

PMID31709530
PMCPMC7211135
OpenAlexW2989549269

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.